EU Pharma Package hits the final stretch—but can negotiators agree?

With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Europe

UPC revives patent, but timing sinks Guardant’s appeal

6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.

Europe

Novo secures website blocking to tackle fake weight-loss drugs

25 June 2026 A UK judge extends a blocking order aimed at ISPs including BT, EE, and Sky, allowing the maker of Ozempic and Wegovy to add infringing sites that sell counterfeits without returning to court.

Europe

UPC hands Occlutech second win against Chinese medtech company in a month

19 June 2026 The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.

More features

UPC revives patent, but timing sinks Guardant’s appeal

LSD trade secrets suit over clinical trail info thrown out by judge

What’s at stake in Australia’s biggest pharma patent appeal in years?

Will Mounjaro and Zepbound get their first US generic rival?

Pfizer’s US Paxlovid patent fight turns on a single error

Novo secures website blocking to tackle fake weight-loss drugs

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

‘Blatant imitation’: Indian court blocks copycat pharma branding

EU Pharma Package hits the final stretch—but can negotiators agree?

More on this story

Editor's picks

Editor's picks

More features